Poster 69: Safety and Efficacy of High-Dose OnabotulinumtoxinA for Post-Stroke Upper Limb Spasticity: Results of a Double-Blind, Placebo-Controlled Trial

Atul Patel: Research Grants - Allergan, Merz, Ipsen; Speakers bureau - Allergan, Merz, Ipsen
Source: PM and R - Category: Rehabilitation Authors: Source Type: research

Related Links:

The President has proposed a $38.7 billion budget for the National Institutes of Health in fiscal year (FY) 2021. This translates to a $3 billion or 7 percent cut in the agency’s funding compared to FY 2020. The NIH budget request includes a $50 million initiative to use artificial intelligence (AI) to develop a better understanding of the causes of chronic diseases and to identify early treatments. This plan is in line with the Administration’s “Industries of the Future” effort, which supports using and developing AI across sectors. The budget would provide $50 million for the Childhood Cancer ...
Source: Public Policy Reports - Category: Biology Authors: Source Type: news
New evidence suggests the Zoster Vaccine Live — administered to prevent shingles — could also reduce the risk of stroke in older adults.Medscape Medical News
Source: Medscape Allergy Headlines - Category: Allergy & Immunology Tags: Neurology & Neurosurgery News Source Type: news
This study establishes baseline sociodemographic and clinical characteristics of hospitalized patients in Nepal who were experiencing heart failure.     Read more   Maternal Health ...
Source: Johns Hopkins University and Health Systems Archive - Category: Nursing Source Type: news
Conclusion: QKLI-IHR is complement activation-related pseudoallergy, rather than an IgE-mediated allergy. QKLI activates C3 and might consequently provoke mast cells to release histamine, which is a principal effector of its IHR. The pseudoallergic reaction induced by QKLI was attributed to the extract of Isatidis Radix. This study suggests a potential therapeutic strategy for the prophylaxis and treatment of QKLI-IHR.
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research
(CNN) — The US Food and Drug Administration on Monday announced the approval of a drug called ubrogepant for the acute treatment of migraine, which could be a new option for people who can’t take or don’t respond to migraine medications currently on the market. The drug will be sold under the name Ubrelvy by the pharmaceutical company Allergan. It is considered effective for migraine with or without aura, referring to the sensory or visual disturbances that occur among roughly a third of migraine sufferers. “Ubrelvy represents an important new option for the acute treatment of migraine in adults, as...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - Category: Consumer Health News Authors: Tags: Health News Syndicated CBSN Boston FDA Migraines Source Type: news
Many people with clinical depression have tried an array of medication and still feel sick. Maybe they’ve tried different selective serotonin reuptake inhibitors (SSRIs) or selective norepinephrine reuptake inhibitors (SNRIs). Maybe they’ve taken these antidepressants along with an antipsychotic (a common strategy to boost effectiveness). Either way, the lack of improvement can make individuals feel even more hopeless and fear the darkness will never lift. If this sounds all-too familiar, you’re definitely not alone. In fact, up to 30 percent of people with depression don’t respond to the first few ...
Source: Psych Central - Category: Psychiatry Authors: Tags: Antidepressants Depression Disorders ECT General Medications Treatment Atypical Depression difficult to treat depression Managing Depression MAOIs medication for depression Monoamine Oxidase Inhibitors Severe Depression Treatin Source Type: news
We describe the first case of MAN2B2 deficiency in a patient with immune dysregulation, developmental delay, and stroke. Altered mannosylation profile was restored in patient cells upon transduction of wild-type MAN2B2.
Source: Journal of Allergy and Clinical Immunology - Category: Allergy & Immunology Authors: Source Type: research
(CNN) — A new drug to treat migraines has shown promise in a large-scale clinical trial, offering hope to people unable to use current treatment options. The drug, ubrogepant, showed greater rates of pain and symptom relief from migraine compared to a placebo, with more than 20% of participants given the drug reporting to be pain-free within two hours and more than 34% relieved of the most bothersome symptoms linked to migraine, which include light and noise sensitivity. This is compared to 14% and 27%, respectively, from the placebo. “Having ubrogepant as a potential new medication for the acute treatment of m...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - Category: Consumer Health News Authors: Tags: Health News CNN Migraines Source Type: news
What can we expect from the flu season this year? Unfortunately, many experts are predicting an active, and possibly severe, flu season. This projection is based on data from Australia, where the flu season is just wrapping up. Australia was hit early and hard by flu this year: over 300,000 patients had laboratory-confirmed influenza, a record number of cases. Flu outbreaks in the Southern Hemisphere happen during our summers, and they often give us a clue as to what we should expect when the flu lands on our shores in the fall. Who should get the flu vaccine? Basically, everybody over the age of 6 months, except for those...
Source: Harvard Health Blog - Category: Consumer Health News Authors: Tags: Cold and Flu Health Prevention Vaccines Source Type: blogs
ConclusionsOur method supported or altered clinical decision-making and treatment in this cohort. A diagnostic tool for PE without intravenous contrast agent or radiation is of great benefit for certain patients.
Source: European Journal of Radiology Open - Category: Radiology Source Type: research
More News: Allergy | Grants | Stroke